The best Side of HOIPIN-1
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To judge numerous intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Most important trial aims had been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis